Supplementary Material from In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

  • Hanwen Wang (Contributor)
  • Oleg Milberg (Contributor)
  • Imke H. Bartelink (Contributor)
  • Paolo Vicini (Contributor)
  • Bing Wang (Contributor)
  • Rajesh Narwal (Contributor)
  • Lorin Roskos (Contributor)
  • Cesar A. Santa-Maria (Contributor)
  • Aleksander S. Popel (Contributor)



Model SBML code
Date made available1 Jan 2019
PublisherUnknown Publisher

Cite this